15 results about "Prior treatment" patented technology

Disclosed herein are methods for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity using a glucagon-like peptide-1 (GLP-1) receptor non-peptide agonist (NPA) compound selected from Compound 1, Compound 1a, Compound 2, Compound 3, pharmaceutically acceptable salts thereof, and hydrates of the compounds and pharmaceutically acceptable salts, by oral administration to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA. Also disclosed herein are uses of a GLP-1 receptor NPA compound for the manufacture of a medicament for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA.

The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

To provide a method for treating patients having HER2-positive metastatic or locally advanced breast cancer in first-line therapy.SOLUTION: A method comprising administering a therapeutically effective amount of an anti-HER2 maytansinoid conjugate to a patient having breast cancer who has received prior treatment with a taxane.SELECTED DRAWING: None

Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.

The present invention relates to the treatment of locally advanced or metastatic urothelial carcinoma (mUC) in a patient suffering from FGFR altered mUC and having disease progression during or after one or more prior treatments comprising a checkpoint inhibitor, in particular an anti-PD-(L) 1 agent, with erdatinib.

The present invention relates generally to methods of treating HER2-positive locally advanced or previously untreated metastatic breast cancer, and particularly provides methods of treating HER2-positive, locally advanced or previously untreated metastatic breast cancer with an anti-HER2-maytansine conjugate (e.g., trastuzumab-eimetanin) that has received prior treatment with a taxane, a method of treating a patient with locally advanced or previously untreated metastatic breast cancer.

The invention discloses a system, an operation method and a prediction processor for predicting a patient to stop prescription treatment. The system includes a memory device storing a training dataset including treatment data and patient data for a group of patients and further including an indication as to whether the patient has stopped treatment of a prescription treatment or procedure, at least one patient prediction model, and patient data and previous treatment data for a patient; and a predictive processor receiving treatment data of the patient from the APD machine, storing the treatment data to a memory device, determining a probability that the patient will stop prescription treatment by applying the patient data of the patient, the treatment data, and previous treatment data to at least one patient predictive model, and causing the probability to be displayed within a user interface on the clinician device.

Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.

This document describes a procedure for treating a subject with multiple myeloma who has received one to three prior treatments. The subject receives infusions of chimeric antigen receptor (CAR) T cells, including a CAR capable of specifically binding to an epitope of BCMA.

This specification provides a method for treating subjects with multiple myeloma who have received one to three prior treatments. The subjects are administered an infusion of chimeric antigen receptor (CAR)-T cells containing CARs that have the ability to specifically bind to the BCMA epitope.

Provided herein are methods of treating a subject who has multiple myeloma and has received prior treatment and has limited treatment options. Infusions of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 x 105 to 5.0 x 106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.

The application discloses application of SKP-SC-EVs in preparation of DPN treatment drugs and belongs to the technical field of biological medicine.The SKP-SC-EVs in the application can be internalized by SCs, and can directly repair and protect damaged SCs in multiple dimensions, laying a good cell foundation for nerve regeneration, in contrast to other source EVs.In addition, through treatment of DPN model rats with the SKP-SC-EVs, it is proved that the SKP-SC-EVs can effectively improve the nerve sensory and motor functions of the DPN rats, promote the regeneration of the nerve structure and myelin sheath of the rats, enhance the nerve internal microcirculation blood flow, delay the atrophy and degenerative changes of the target muscle, and realize systematic repair of the three functional units of "nerve-vascular-muscle".The DPN treatment scheme provided by the application effectively overcomes the defects in the prior treatment schemes, i.e., single repair effect dimension and difficulty in realizing fundamental reconstruction of nerve functions and keeping long-term stability.

The invention discloses external traditional Chinese medicine essential oil for treating atopic dermatitis, which is prepared by dissolving fructus cannabis powder and semen coicis powder in oil according to a mass ratio of 1: (0.1-5), the mass volume ratio of the fructus cannabis powder to the oil is 0.05-0.5 kg / L, and the mass volume ratio of the semen coicis powder to the oil is 0.05-0.5 kg / L; the traditional Chinese medicine essential oil can effectively improve inflammation symptoms of atopic dermatitis, corresponding dosage forms can be adopted according to different stages of diseases, and therefore the technical problems that in the existing treatment technology, traditional Chinese medicine for oral administration is too many in medicine flavor and high in cost, and traditional Chinese medicine preparations for external use are lacked are solved.

The present disclosure provides methods for using a peptide of an oncogenic protein to reverse immune suppression, cause stronger immune responses, lower cancer recurrence rates, and lengthen disease-free survival. The suppressed immune state can be due to prior treatments, including but not limited to surgery, chemotherapy, antibodies targeting the oncogenic protein, high levels of expression of the oncogenic protein, or combination thereof. It has been demonstrated that if GM-CSF is administered to patients without the peptide from the oncogenic protein, such as in the control group of a clinical study, the immune response to GM-CSF alone is lower when compared to patients who are not treated with an antibody to the oncogenic protein and who do not have high levels of expression of the oncogenic protein: their immune state is suppressed, recurrence rate is higher, and disease free survival is lower, which are all reversed by the addition of the peptide.

Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.